<?xml version='1.0' encoding='utf-8'?>
<document id="25249693"><sentence text="In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent." /><sentence text="N-(2,4-dichlorophenyl)-5-methyl-1,2-oxazole-3-carboxamide (UTL-5g), a potential chemo- and radioprotective agent, acts as a prodrug requiring bioactivation to the active metabolite 5-methylisoxazole-3-carboxylic acid (ISOX)"><entity charOffset="0-57" id="DDI-PubMed.25249693.s2.e0" text="N-(2,4-dichlorophenyl)-5-methyl-1,2-oxazole-3-carboxamide" /><entity charOffset="181-216" id="DDI-PubMed.25249693.s2.e1" text="5-methylisoxazole-3-carboxylic acid" /><entity charOffset="218-222" id="DDI-PubMed.25249693.s2.e2" text="ISOX" /><pair ddi="false" e1="DDI-PubMed.25249693.s2.e0" e2="DDI-PubMed.25249693.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25249693.s2.e0" e2="DDI-PubMed.25249693.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25249693.s2.e0" e2="DDI-PubMed.25249693.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25249693.s2.e1" e2="DDI-PubMed.25249693.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25249693.s2.e1" e2="DDI-PubMed.25249693.s2.e2" /></sentence><sentence text=" UTL-5g hydrolysis to ISOX and 2,4-dichloroaniline (DCA) has been identified in porcine and rabbit liver esterases"><entity charOffset="31-50" id="DDI-PubMed.25249693.s3.e0" text="2,4-dichloroaniline" /><entity charOffset="52-55" id="DDI-PubMed.25249693.s3.e1" text="DCA" /><entity charOffset="22-24" id="DDI-PubMed.25249693.s3.e2" text="ISOX" /><pair ddi="false" e1="DDI-PubMed.25249693.s3.e2" e2="DDI-PubMed.25249693.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25249693.s3.e2" e2="DDI-PubMed.25249693.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25249693.s3.e2" e2="DDI-PubMed.25249693.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25249693.s3.e0" e2="DDI-PubMed.25249693.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25249693.s3.e0" e2="DDI-PubMed.25249693.s3.e1" /></sentence><sentence text=" The purpose of this study was to provide insights on the metabolism and drug interaction potential of UTL-5g in humans" /><sentence text=" The kinetics of UTL-5g hydrolysis was determined in human liver microsomes (HLM) and recombinant human carboxylesterases (hCE1b and hCE2)" /><sentence text=" The potential of UTL-5g and its metabolites for competitive inhibition and time-dependent inhibition of microsomal cytochrome P450 (P450) was examined in HLM" /><sentence text=" UTL-5g hydrolysis to ISOX and DCA in HLM were NADPH-independent, with a maximum rate of reaction (Vmax) of 11"><entity charOffset="47-52" id="DDI-PubMed.25249693.s7.e0" text="NADPH" /><entity charOffset="22-26" id="DDI-PubMed.25249693.s7.e1" text="ISOX" /><entity charOffset="31-35" id="DDI-PubMed.25249693.s7.e2" text="DCA" /><pair ddi="false" e1="DDI-PubMed.25249693.s7.e1" e2="DDI-PubMed.25249693.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25249693.s7.e1" e2="DDI-PubMed.25249693.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25249693.s7.e1" e2="DDI-PubMed.25249693.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25249693.s7.e2" e2="DDI-PubMed.25249693.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25249693.s7.e2" e2="DDI-PubMed.25249693.s7.e0" /></sentence><sentence text="1 nmol/min per mg and substrate affinity (Km) of 41" /><sentence text="6 µM" /><sentence text=" Both hCE1b and hCE2 effectively catalyzed UTL-5g hydrolysis, but hCE2 exhibited ∼30-fold higher catalytic efficiency (Vmax/Km) than hCE1b" /><sentence text=" UTL-5g and DCA competitively inhibited microsomal CYP1A2, CYP2B6, and CYP2C19 (IC50 values &lt;50 µM), and exhibited time-dependent inhibition of microsomal CYP1A2 with the inactivation efficiency (kinact/KI) of 0"><entity charOffset="12-14" id="DDI-PubMed.25249693.s11.e0" text="DCA" /></sentence><sentence text="68 and 0" /><sentence text="51 minute(-1)·mM(-1), respectively" /><sentence text=" ISOX did not inhibit or inactivate any tested microsomal P450"><entity charOffset="1-3" id="DDI-PubMed.25249693.s14.e0" text="ISOX" /></sentence><sentence text=" In conclusion, hCE1b and hCE2 play a key role in the bioactivation of UTL-5g" /><sentence text=" Factors influencing carboxylesterase activities may have a significant impact on the pharmacological and therapeutic effects of UTL-5g" /><sentence text=" UTL-5g has the potential to inhibit P450-mediated metabolism through competitive inhibition or time-dependent inhibition" /><sentence text=" Caution is particularly needed for potential drug interactions involving competitive inhibition or time-dependent inhibition of CYP1A2 in the future clinical development of UTL-5g" /><sentence text="" /></document>